

DAFTAR PUSTAKA

- Ageno, W., Gallus, A.S., Wittkowsky, A., Crowther, M., Hylek, E.M., Palareti, G., 2012. Oral Anticoagulant Therapy. *Chest* 141, e44S-e88S. <https://doi.org/10.1378/chest.11-2292>
- Albertsen, I.E., Overvad, T.F., Lip, G.Y.H., Larsen, T.B., 2015. Smoking, atrial fibrillation, and ischemic stroke: a confluence of epidemics. *Curr. Opin. Cardiol.* 30, 512–517. <https://doi.org/10.1097/HCO.0000000000000205>
- Alkhouli, M., Alqahtani, F., Aljohani, S., Alvi, M., Holmes, D.R., 2018. Burden of Atrial Fibrillation–Associated Ischemic Stroke in the United States. *JACC Clin. Electrophysiol.* 4, 618–625. <https://doi.org/10.1016/j.jacep.2018.02.021>
- Alqahtani, F., Aljohani, S., Tarabishy, A., Busu, T., Adcock, A., Alkhouli, M., 2017. Incidence and Outcomes of Myocardial Infarction in Patients Admitted With Acute Ischemic Stroke. *Am. Heart Assoc.* 48, 8. <https://doi.org/10.1161/STROKEAHA.117.018408>
- Andersen, S.D., Gorst-Rasmussen, A., Lip, G.Y.H., Bach, F.W., Larsen, T.B., 2015. Recurrent Stroke: The Value of the CHA₂DS₂ VASc Score and the Essen Stroke Risk Score in a Nationwide Stroke Cohort. *Stroke* 46, 2491–2497. <https://doi.org/10.1161/STROKEAHA.115.009912>
- Apostolakis, S., Lane, D.A., Guo, Y., Buller, H., Lip, G.Y.H., 2012. Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk–Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation. *J. Am. Coll. Cardiol.* 60, 861–867. <https://doi.org/10.1016/j.jacc.2012.06.019>
- Arboix, A., 2015. Cardiovascular Risk Factors For Acute Stroke: Risk Profiles in the Different Subtypes of Ischemic Stroke. *World J. Clin. Cases* 3(5), 418–429.
- ASA, 2020. Explaining Stroke. *Am. Heart Assoc.* 20.
- Ball, J., 2017. Which anticoagulant for stroke prevention in atrial fibrillation? *BMJ* j5399. <https://doi.org/10.1136/bmj.j5399>
- Bansal, S., Sangha, K.S., Khatri, P., 2013. Drug Treatment of Acute Ischemic Stroke. *Am. J. Cardiovasc. Drugs* 13, 57–69. <https://doi.org/10.1007/s40256-013-0007-6>
- Barnes, G.D., 2020. Combining antiplatelet and anticoagulant therapy in cardiovascular disease. *Hematology* 2020, 642–648. <https://doi.org/10.1182/hematology.2020000151>
- Baser, O., Du, J., Xie, L., Baser, E., 2011. PCV35 COMPARISON OF MAJOR BLEEDING RELATED MORTALITY, HEALTH CARE UTILIZATION AND COSTS OF PATIENTS WITH NON-VALVULAR ATRIAL

FIBRILLATION. Value Health 14, A38.
<https://doi.org/10.1016/j.jval.2011.02.223>

Bassand, J.-P., Accetta, G., Al Mahmeed, W., Corbalan, R., Eikelboom, J., Fitzmaurice, D.A., Fox, K.A.A., Gao, H., Goldhaber, S.Z., Goto, S., Haas, S., Kayani, G., Pieper, K., Turpie, A.G.G., van Eickels, M., Verheugt, F.W.A., Kakkar, A.K., for the GARFIELD-AF Investigators, 2018. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLOS ONE 13, e0191592.
<https://doi.org/10.1371/journal.pone.0191592>

Basu, E., Salehi Omran, S., Kamel, H., Parikh, N.S., 2021. Sex differences in the risk of recurrent ischemic stroke after ischemic stroke and transient ischemic attack. Eur. Stroke J. 6, 367–373.
<https://doi.org/10.1177/23969873211058568>

Benjamin, E.J., Blaha, M.J., Chiuve, S.E., Cushman, M., Das, S.R., Deo, R., de Ferranti, S.D., Floyd, J., Fornage, M., Gillespie, C., Isasi, C.R., Jiménez, M.C., Jordan, L.C., Judd, S.E., Lackland, D., Lichtman, J.H., Lisabeth, L., Liu, S., Longenecker, C.T., Mackey, R.H., Matsushita, K., Mozaffarian, D., Mussolino, M.E., Nasir, K., Neumar, R.W., Palaniappan, L., Pandey, D.K., Thiagarajan, R.R., Reeves, M.J., Ritchey, M., Rodriguez, C.J., Roth, G.A., Rosamond, W.D., Sasson, C., Towfighi, A., Tsao, C.W., Turner, M.B., Virani, S.S., Voeks, J.H., Willey, J.Z., Wilkins, J.T., Wu, J.H.Y., Alger, H.M., Wong, S.S., Muntner, P., 2017. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation 135. <https://doi.org/10.1161/CIR.0000000000000485>

Birman-Deych, E., Radford, M.J., Nilasena, D.S., Gage, B.F., 2006. Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation. Stroke 37, 1070–1074.
<https://doi.org/10.1161/01.STR.0000208294.46968.a4>

Bonde, A., Lip, G., Kamper, A.-L., Staerk, L., Torp-Pedersen, C., Gislason, G., Olesen, J., 2017. Renal Function, Time in Therapeutic Range and Outcomes in Warfarin-Treated Atrial Fibrillation Patients: A Retrospective Analysis of Nationwide Registries. Thromb. Haemost. 117, 2291–2299.
<https://doi.org/10.1160/TH17-03-0198>

Boonyawat, K., Caron, F., Li, A., Chai-Adisaksopha, C., Lim, W., Iorio, A., Lopes, R.D., Garcia, D., Crowther, M.A., 2017. Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. J. Thromb. Haemost. 15, 1322–1333. <https://doi.org/10.1111/jth.13701>

Bruins Slot, K.M., Berge, E., 2018. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with

atrial fibrillation. Cochrane Database Syst. Rev.
<https://doi.org/10.1002/14651858.CD008980.pub3>

- Bustamante, A., Giralt, D., García-Berrocso, T., Rubiera, M., Álvarez-Sabín, J., Molina, C., Serena, J., Montaner, J., 2017. The impact of post-stroke complications on in-hospital mortality depends on stroke severity. *Eur. Stroke J.* 2, 54–63. <https://doi.org/10.1177/2396987316681872>
- Castellano, J.M., Chinitz, J., Willner, J., Fuster, V., 2014. Mechanisms of Stroke in Atrial Fibrillation. *Card. Electrophysiol. Clin.* 6, 5–15. <https://doi.org/10.1016/j.ccep.2013.10.007>
- Chan, Y., See, L., Tu, H., Yeh, Y., Chang, S., Wu, L., Lee, H., Wang, C., Kuo, Chang-Fu, Kuo, Chi-Tai, 2018. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation. *J. Am. Heart Assoc.* 7, e008150. <https://doi.org/10.1161/JAHA.117.008150>
- Chan, Y.-H., Yen, K.-C., See, L.-C., Chang, S.-H., Wu, L.-S., Lee, H.-F., Tu, H.-T., Yeh, Y.-H., Kuo, C.-T., 2016. Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation. *Stroke* 47, 441–449. <https://doi.org/10.1161/STROKEAHA.115.011476>
- Chang, K.-W., Xian, Y., Zhao, X., Mi, X., Matsouaka, R., Schwamm, L.H., Shah, S., Lytle, B.L., Smith, E.E., Bhatt, D.L., Fonarow, G.C., Hsu, J.C., 2020. Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke. *Int. J. Cardiol.* 321, 88–94. <https://doi.org/10.1016/j.ijcard.2020.08.011>
- Chen, J., Li, S., Zheng, K., Wang, H., Xie, Y., Xu, P., Dai, Z., Gu, M., Xia, Y., Zhao, M., Liu, X., Xu, G., 2019. Impact of Smoking Status on Stroke Recurrence. *J. Am. Heart Assoc.* 8. <https://doi.org/10.1161/JAHA.118.011696>
- Chen, L.-F., Chang, C.-Y., Hsu, L.-C., Tsai, P.-H., Chang, S.-J., Chang, S.-C., Yuan, M.-K., Lai, Y.-C., Liu, Y.-C., Wang, W.-S., 2013. Bacterial pneumonia following acute ischemic stroke. *J. Chin. Med. Assoc.* 76, 78–82. <https://doi.org/10.1016/j.jcma.2012.10.005>
- Cho, H.-J., Kang, Y.J., Sung, S.M., Ahn, S.-H., Jung, Y.H., Lee, K.-Y., Seo, J.H., Han, S.W., Park, J.H., Choi, H.-Y., Kwon, J.-H., Kim, W.-J., Park, H.J., Choi, J.K., Nam, H.S., Heo, J.H., Kim, Y.D., 2020. Effects of dabigatran and rivaroxaban on stroke severity according to the results of routine coagulation tests. *PLOS ONE* 15, e0240483. <https://doi.org/10.1371/journal.pone.0240483>
- Coleman, C.I., Peacock, W.F., Bunz, T.J., Alberts, M.J., 2017. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or

- Transient Ischemic Attack. *Stroke* 48, 2142–2149.
<https://doi.org/10.1161/STROKEAHA.117.017474>
- Dahal, K., Kunwar, S., Rijal, J., Schulman, P., Lee, J., 2016. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease. *Chest* 149, 951–959.
<https://doi.org/10.1378/chest.15-1719>
- de Jonge, J.C., van de Beek, D., Lyden, P., Brady, M.C., Bath, P.M., van der Worp, H.B., Lees, K.R., Alexandrov, A., Berge, E., Bluhmki, E., Bornstein, N., Chen, C., Claesson, L., Davis, S.M., Donnan, G., Diener, H.C., Fisher, M., Ginsberg, M., Gregson, B., Grotta, J., Hacke, W., Hennerici, M.G., Hommel, M., Kaste, M., Marler, J., Muir, K., Venketasubramanian, N., Sacco, R., Shuaib, A., Teal, P., Wahlgren, N.G., Warach, S., Weimar, C., 2022. Temporal Profile of Pneumonia After Stroke. *Stroke* 53, 53–60.
<https://doi.org/10.1161/STROKEAHA.120.032787>
- Ding, W.Y., Gupta, D., Lip, G.Y.H., 2020a. Atrial fibrillation and the prothrombotic state: revisiting Virchow's triad in 2020. *Heart* 106, 1463–1468. <https://doi.org/10.1136/heartjnl-2020-316977>
- Ding, W.Y., Harrison, S., Gupta, D., Lip, G.Y.H., Lane, D.A., 2020b. Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies. *Front. Med.* 7, 54.
<https://doi.org/10.3389/fmed.2020.00054>
- Dong, J., Wang, F., Sundararajan, S., 2020. Use of Dual Antiplatelet Therapy Following Ischemic Stroke. *Stroke* 51.
<https://doi.org/10.1161/STROKEAHA.119.028400>
- Douketis, J.D., Spyropoulos, A.C., Kaatz, S., Becker, R.C., Caprini, J.A., Dunn, A.S., Garcia, D.A., Jacobson, A., Jaffer, A.K., Kong, D.F., Schulman, S., Turpie, A.G.G., Hasselblad, V., Ortel, T.L., 2015. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. *N. Engl. J. Med.* 373, 823–833. <https://doi.org/10.1056/NEJMoa1501035>
- Douros, A., Durand, M., Doyle, C.M., Yoon, S., Reynier, P., Fillion, K.B., 2019. Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies. *Drug Saf.* 42, 1135–1148.
<https://doi.org/10.1007/s40264-019-00842-1>
- El-Hajj, M., Salameh, P., Rachidi, S., Hosseini, H., 2016. The epidemiology of stroke in the Middle East. *Eur. Stroke J.* 19.
- Falk, G.E., Rogers, J., Lu, L., Ablah, E., Okut, H., Vindhya, M.R., 2022. Sepsis, Septic Shock, and Differences in Cardiovascular Event Occurrence. *J. Intensive Care Med.* 088506662210836.
<https://doi.org/10.1177/08850666221083644>

- Fang, M.C., Singer, D.E., Chang, Y., Hylek, E.M., Henault, L.E., Jensvold, N.G., Go, A.S., 2005. Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study. *Circulation* 112, 1687–1691. <https://doi.org/10.1161/CIRCULATIONAHA.105.553438>
- Farooque, U., Lohano, A.K., Kumar, A., Karimi, S., Yasmin, F., Bollampally, V.C., Ranpariya, M.R., 2020. Validity of National Institutes of Health Stroke Scale for Severity of Stroke to Predict Mortality Among Patients Presenting With Symptoms of Stroke. *Cureus*. <https://doi.org/10.7759/cureus.10255>
- Feistritzer, H.-J., Desch, S., Zeymer, U., Fuernau, G., de Waha-Thiele, S., Dudek, D., Huber, K., Stepinska, J., Schneider, S., Ouarrak, T., Thiele, H., 2019. Prognostic Impact of Atrial Fibrillation in Acute Myocardial Infarction and Cardiogenic Shock: Results From the CULPRIT-SHOCK Trial. *Circ. Cardiovasc. Interv.* 12, e007661. <https://doi.org/10.1161/CIRCINTERVENTIONS.118.007661>
- Feiz, F., Sedghi, R., Salehi, A., Hatam, N., Bahmei, J., Borhani-Haghighi, A., 2016. Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation. *J. Vasc. Interv. Neurol.* 9, 7.
- Fitzakerley, D.J., 2006. Anticoagulant, Thrombolytic and Anti-Platelet Drugs. 21.
- Fonarow, G.C., Saver, J.L., Smith, E.E., Broderick, J.P., Kleindorfer, D.O., Sacco, R.L., Pan, W., Olson, D.M., Hernandez, A.F., Peterson, E.D., Schwamm, L.H., 2012. Relationship of National Institutes of Health Stroke Scale to 30-Day Mortality in Medicare Beneficiaries With Acute Ischemic Stroke. *J. Am. Heart Assoc.* 1, e000034. <https://doi.org/10.1161/JAHA.111.000034>
- Gami, A.S., 2005. Anticoagulant plus antiplatelet treatment increased the risk of bleeding in atrial fibrillation. *Evid. Based Med.* 10, 56–56. <https://doi.org/10.1136/ebm.10.2.56>
- Gattringer, T., Posekany, A., Niederkorn, K., Knoflach, M., Poltrum, B., Mutzenbach, S., Haring, H.-P., Ferrari, J., Lang, W., Willeit, J., Kiechl, S., Enzinger, C., Fazekas, F., for the Austrian Stroke Unit Registry Collaborators, 2019. Predicting Early Mortality of Acute Ischemic Stroke: Score-Based Approach. *Stroke* 50, 349–356. <https://doi.org/10.1161/STROKEAHA.118.022863>
- Gebreyohannes, E.A., Bhagavathula, A.S., Abebe, T.B., Seid, M.A., Haile, K.T., 2019. In-Hospital Mortality among Ischemic Stroke Patients in Gondar University Hospital: A Retrospective Cohort Study. *Stroke Res. Treat.* 2019, 1–7. <https://doi.org/10.1155/2019/7275063>
- George Institute for Global Health, 2017. Reducing The Burden of Cardiovascular Disease in Indonesia Evidence Review. Cardiovascular Division Health Services Research Centre, Newtown.

- Gulilat, M., Jandoc, R., Jeyakumar, N., McArthur, E., Garg, A.X., Kim, R.B., Tirona, R.G., Schwarz, U.I., 2022. Association of Sex With Stroke and Bleeding Risk of Apixaban and Rivaroxaban in Elderly Atrial Fibrillation Patients Using Propensity Score Weights. *CJC Open* 4, 56–64. <https://doi.org/10.1016/j.cjco.2021.09.002>
- Gutierrez, C., Blanchard, D.G., 2016. Diagnosis and Treatment of Atrial Fibrillation. *Atr. Fibrillation* 94, 11.
- Gutierrez, C., Blanchard, D.G., 2011. Atrial Fibrillation: Diagnosis and Treatment. *Atr. Fibrillation* 83, 8.
- Hakma, Z., Stofko, D., Binning, M., Liebman, K., Veznedaroglu, E., 2014. Retrospective study of Heparin Administration for Ischemic Stroke when there is an IV-tPA Contraindication. *Surg. Neurol. Int.* 5, 62. <https://doi.org/10.4103/2152-7806.132032>
- Hamrah, M.S., Hamrah, Mohammad Hassan, Hamrah, Mohammad Hussain, Hamrah, E., Dahi, T., Musammen, M.N., Hamrah, Mohammad Hashem, 2019. An Overview of Anticoagulants. *CPQ Med.* 6(3), 01–09.
- Han, J., Bae, H.-J., Wong, L.K.S., 2011. Pathophysiology and Mechanisms Whereby Hypertension May Cause Stroke, in: Aiyagari, V., Gorelick, P.B. (Eds.), *Hypertension and Stroke*. Humana Press, Totowa, NJ, pp. 77–94. https://doi.org/10.1007/978-1-60761-010-6_5
- Hansen, M.L., Sørensen, R., Clausen, M.T., Fog-Petersen, M.L., Raunsø, J., Gadsbøll, N., Gislason, G.H., Folke, F., Andersen, S.S., Schramm, T.K., Abildstrøm, S.Z., Poulsen, H.E., Køber, L., Torp-Pedersen, C., 2010. Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation. *Arch. Intern. Med.* 170. <https://doi.org/10.1001/archinternmed.2010.271>
- Hapsari, D.C., Kusharwanti, W., 2014. Efektivitas dan Keamanan Antikoagulan Pada Sindroma Koroner Akut Tanpa Elevasi Segmen ST. *J. Manaj. Dan Pelayanan Farm.* 4, 6.
- Harskamp, R.E., Lucassen, W.A.M., Lopes, R.D., Himmelreich, J.C.L., Parati, G., Weert, H.C.P.M. van, 2021. Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. *Acta Cardiol.* 1–5. <https://doi.org/10.1080/00015385.2021.1882111>
- Hasegawa, S., Okada, A., Aso, S., Kumazawa, R., Matsui, H., Fushimi, K., Yasunaga, H., Nangaku, M., 2022. Association Between Diabetes and Major Bleeding Complications of Renal Biopsy. *Kidney Int. Rep.* 7, 232–240. <https://doi.org/10.1016/j.ekir.2021.11.013>
- Hernandez, I., Zhang, Y., Saba, S., 2018. Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With

- Atrial Fibrillation. *Am. J. Cardiol.* 122, 69–75.
<https://doi.org/10.1016/j.amjcard.2018.03.012>
- Heuschmann, P.U., Kolominsky-Rabas, P.L., Misselwitz, B., Hermanek, P., Leffrman, C., Janzen, R.W.C., Rother, J., Buecker-Nott, H.-J., Berger, K., 2004. Predictors of In-Hospital Mortality and Attributable Risks of Death After Ischemic Stroke: The German Stroke Registers Study Group. *ARCH INTERN MED* 164, 8.
- Hojs Fabjan, T., Hojs, R., 2014. Stroke and renal dysfunction. *Eur. J. Intern. Med.* 25, 18–24. <https://doi.org/10.1016/j.ejim.2013.08.710>
- Hsieh, Y.-C., Tsou, P.-Y., Wang, Y.-H., Chao, C.C.-T., Lee, W.-C., Lee, M.G., Wu, J.-Y., Chang, S.-S., Chen, P.-Y., Lee, C.-C., 2020. Risk Factors for Myocardial Infarction and Stroke Among Sepsis Survivors: A Competing Risks Analysis. *J. Intensive Care Med.* 35, 34–41.
<https://doi.org/10.1177/0885066619844936>
- Huang, C.-W., Duan, L., An, J., Sim, J.J., Lee, M.-S., 2021. Effectiveness and Safety of Dabigatran in Atrial Fibrillation Patients with Severe Obesity: a Real-World Retrospective Cohort Study. *J. Gen. Intern. Med.*
<https://doi.org/10.1007/s11606-021-07114-8>
- Hughes, M., Lip, G.Y.H., 2007. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. *QJM* 100, 599–607. <https://doi.org/10.1093/qjmed/hcm076>
- Hylek, E.M., Held, C., Alexander, J.H., Lopes, R.D., De Caterina, R., Wojdyla, D.M., Huber, K., Jansky, P., Steg, P.G., Hanna, M., Thomas, L., Wallentin, L., Granger, C.B., 2014. Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin. *J. Am. Coll. Cardiol.* 63, 2141–2147.
<https://doi.org/10.1016/j.jacc.2014.02.549>
- Induruwa, I., Hennebry, E., Hennebry, J., Thakur, M., Warburton, E.A., Khadjooi, K., 2022. Sepsis-driven atrial fibrillation and ischaemic stroke. Is there enough evidence to recommend anticoagulation? *Eur. J. Intern. Med.* 98, 32–36. <https://doi.org/10.1016/j.ejim.2021.10.022>
- Issa, John MM, Douglas PZ, 2012. Clinical Arrhythmology and Electrophysiology: A Companion to Braunwald's Heart Disease. Elsevier.
<https://doi.org/10.1016/C2010-0-68723-2>
- Jaffe, T.A., Raiff, D., Ho, L.M., Kim, C.Y., 2015. Management of Anticoagulant and Antiplatelet Medications in Adults Undergoing Percutaneous Interventions. *Am. J. Roentgenol.* 205, 421–428.
<https://doi.org/10.2214/AJR.14.13342>
- Jeger, R.V., Assmann, S.F., Yehudai, L., Ramanathan, K., Farkouh, M.E., Hochman, J.S., 2007. Causes of death and re-hospitalization in cardiogenic shock. *Acute Card. Care* 9, 25–33.
<https://doi.org/10.1080/17482940601178039>

- Johnson, S.G., Witt, D.M., Eddy, T.R., Delate, T., 2007. Warfarin and Antiplatelet Combination Use Among Commercially Insured Patients Enrolled in an Anticoagulation Management Service. *Chest* 131, 1500–1507. <https://doi.org/10.1378/chest.06-2374>
- Jun, M., James, M.T., Manns, B.J., Quinn, R.R., Ravani, P., Tonelli, M., Perkovic, V., Winkelmayer, W.C., Ma, Z., Hemmelgarn, B.R., for the Alberta Kidney Disease Network, 2015. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. *BMJ* 350, h246–h246. <https://doi.org/10.1136/bmj.h246>
- Jung, H., Yang, P.-S., Jang, E., Yu, H.T., Kim, T.-H., Uhm, J.-S., Kim, J.-Y., Pak, H.-N., Lee, M.-H., Joung, B., Lip, G.Y.H., 2019. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy. *Chest* 155, 354–363. <https://doi.org/10.1016/j.chest.2018.11.009>
- Kai, B., Bogorad, Y., Nguyen, L.-A.N., Yang, S.-J., Chen, W., Spencer, H.T., Shen, A.Y.-J., Lee, M.-S., 2017. Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation. *Heart Rhythm* 14, 645–651. <https://doi.org/10.1016/j.hrthm.2017.01.047>
- Kanyal, N., 2015. The Science of Ischemic Stroke: Pathophysiology & Pharmacological Treatment. *Int. J. Pharma Res. Rev.* 4(10), 65–84.
- Kapil, N., Datta, Y.H., Alakbarova, N., Bershad, E., Selim, M., Liebeskind, D.S., Bachour, O., Rao, G.H.R., Divani, A.A., 2017. Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke. *Clin. Appl. Thromb.* 23, 301–318. <https://doi.org/10.1177/1076029616660762>
- Khan, A.A., Lip, G.Y.H., 2018. Role of chronic kidney disease and atrial fibrillation in outcomes of patients with ischemic stroke. *Eur. J. Neurol.* 25, 1009–1010. <https://doi.org/10.1111/ene.13664>
- Kim, D., Yang, P.-S., Sung, J.-H., Jang, E., Yu, H.T., Kim, T.-H., Uhm, J.-S., Kim, J.-Y., Pak, H.-N., Lee, M.-H., Lip, G.Y.H., Joung, B., 2022. Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation. *Stroke* STROKEAHA121036757. <https://doi.org/10.1161/STROKEAHA.121.036757>
- Kim, T.-H., Yang, P.-S., Yu, H.T., Jang, E., Shin, H., Kim, H.Y., Uhm, J.-S., Kim, J.-Y., Sung, J.-H., Pak, H.-N., Lee, M.-H., Joung, B., Lip, G.Y.H., 2019. Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population. *Eur. Heart J.* 40, 809–819. <https://doi.org/10.1093/eurheartj/ehy877>
- Kim, T.-H., Yang, P.-S., Yu, H.T., Jang, E., Uhm, J.-S., Kim, J.-Y., Pak, H.-N., Lee, M.-H., Joung, B., Lip, G.Y.H., 2018. Age Threshold for Ischemic

- Stroke Risk in Atrial Fibrillation: Cohort Data Covering the Entire Korean Population. *Stroke* 49, 1872–1879. <https://doi.org/10.1161/STROKEAHA.118.021047>
- Kim, Y.-H., Roh, S.-Y., 2016. The Mechanism of and Preventive Therapy for Stroke in Patients with Atrial Fibrillation 18, 9.
- Kimura, K., 2005. Atrial fibrillation as a predictive factor for severe stroke and early death in 15 831 patients with acute ischaemic stroke. *J. Neurol. Neurosurg. Psychiatry* 76, 679–683. <https://doi.org/10.1136/jnnp.2004.048827>
- Kirchhof, P., Haas, S., Amarenco, P., Hess, S., Lambelet, M., van Eickels, M., Turpie, A.G.G., Camm, A.J., the XANTUS Investigators*, 2020. Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. *J. Am. Heart Assoc.* 9, e009530. <https://doi.org/10.1161/JAHA.118.009530>
- Kjerpeseth, L.J., Selmer, R., Ariansen, I., Karlstad, Ø., Ellekjær, H., Skovlund, E., 2019. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study. *PLOS ONE* 14, e0221500. <https://doi.org/10.1371/journal.pone.0221500>
- Klatsky, A.L., Friedman, G.D., Sidney, S., Kipp, H., Kubo, A., Armstrong, M.A., 2005. Risk of Hemorrhagic Stroke in Asian American Ethnic Groups. *Neuroepidemiology* 25, 26–31. <https://doi.org/10.1159/000085310>
- Kolmos, M., Christoffersen, L., Kruuse, C., 2021. Recurrent Ischemic Stroke – A Systematic Review and Meta-Analysis. *J. Stroke Cerebrovasc. Dis.* 30, 105935. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105935>
- Kuriakose, D., Xiao, Z., 2020. Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. *Int. J. Mol. Sci.* 21, 7609. <https://doi.org/10.3390/ijms21207609>
- Kusuima, Y., Venketasubramanian, N., Kiemas, L.S., Misbach, J., 2009. Burden of Stroke in Indonesia. *Int. J. Stroke* 4, 379–380. <https://doi.org/10.1111/j.1747-4949.2009.00326.x>
- Lackland, D.T., Roccella, E.J., Deutsch, A.F., Fornage, M., George, M.G., Howard, G., Kissela, B.M., Kittner, S.J., Lichtman, J.H., Lisabeth, L.D., Schwamm, L.H., Smith, E.E., Towfighi, A., 2014. Factors Influencing the Decline in Stroke Mortality: A Statement From the American Heart Association/American Stroke Association. *Stroke* 45, 315–353. <https://doi.org/10.1161/01.str.0000437068.30550.cf>
- Langsted, A., Nordestgaard, B., 2019. Smoking is Associated with Increased Risk of Major Bleeding: A Prospective Cohort Study. *Thromb. Haemost.* 119, 039–047. <https://doi.org/10.1055/s-0038-1675798>

- Lau, Y.C., Proietti, M., Guiducci, E., Blann, A.D., Lip, G.Y.H., 2016. Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease. *J. Am. Coll. Cardiol.* 68, 1452–1464. <https://doi.org/10.1016/j.jacc.2016.06.057>
- Lee, H.-J., Kim, H.-K., Kim, B.-S., Han, K.-D., Park, J.-B., Lee, H., Lee, S.-P., Kim, Y.-J., 2021. Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy. *PLOS ONE* 16, e0253310. <https://doi.org/10.1371/journal.pone.0253310>
- Lee, S.-R., Choi, E.-K., Han, K.-D., Jung, J.-H., Oh, S., Lip, G.Y.H., 2019. Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation. *Sci. Rep.* 9, 6690. <https://doi.org/10.1038/s41598-019-43224-4>
- Levine, G.N. (Ed.), 2018. *Cardiology secrets*, Fifth edition. ed, Secrets. Elsevier, Philadelphia, PA.
- Li, H., Ye, S., Wu, Y.-L., Huang, S.-M., Li, Y.-X., Lu, K., Huang, J.-B., Chen, L., Li, H.-Z., Wu, W.-J., Wu, Z.-L., Wu, J.-Z., Zhong, W.-T., Xian, W.-C., Liao, F., Tung, T.-H., Wu, Q.-L., Chen, H., Yuan, L., Yang, Z., Huang, L.-A., 2021. Predicting mortality in acute ischaemic stroke treated with mechanical thrombectomy: analysis of a multicentre prospective registry. *BMJ Open* 11, e043415. <https://doi.org/10.1136/bmjopen-2020-043415>
- Li, X., Pathadka, S., Man, K.K.C., Ng, V.W.S., Siu, C.W., Wong, I.C.K., Chan, E.W., Lau, W.C.Y., 2020. Comparative Outcomes Between Direct Oral Anticoagulants, Warfarin, and Antiplatelet Monotherapy Among Chinese Patients with Atrial Fibrillation: A Population-Based Cohort Study. *Drug Saf.* 43, 1023–1033. <https://doi.org/10.1007/s40264-020-00961-0>
- Liabeuf, S., Scaltieux, L.-M., Masmoudi, K., Roussel, B., Moragny, J., Andrejak, M., Gras-Champel, V., 2015. Risk Factors for Bleeding in Hospitalized at Risk Patients With an INR of 5 or More Treated With Vitamin K Antagonists. *Medicine (Baltimore)* 94, e2366. <https://doi.org/10.1097/MD.0000000000002366>
- Lin, K.J., Hernández, S., Rodríguez, L.A.G., 2011. Acid Suppressants Reduce Risk of Gastrointestinal Bleeding in Patients on Antithrombotic or Anti-Inflammatory Therapy 141, 9.
- Lin, M.C., Streja, E., Soohoo, M., Hanna, M., Savoj, J., Kalantar-Zadeh, K., Lau, W.L., 2017. Warfarin Use and Increased Mortality in End-Stage Renal Disease. *Am. J. Nephrol.* 46, 249–256. <https://doi.org/10.1159/000481207>
- Lin, S.-F., Lu, Y.-H., Bai, C.-H., 2020. Risk of recurrent stroke for Asian stroke patients treated with non-vitamin K antagonist oral anticoagulant and warfarin. *Ther. Adv. Chronic Dis.* 11, 204062232097485. <https://doi.org/10.1177/2040622320974853>

- Lip, G.Y.H., Clementy, N., Pericart, L., Banerjee, A., Fauchier, L., 2015. Stroke and Major Bleeding Risk in Elderly Patients Aged ≥ 75 Years With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. *Stroke* 46, 143–150. <https://doi.org/10.1161/STROKEAHA.114.007199>
- Lip, G.Y.H., Freedman, B., De Caterina, R., Potpara, T.S., 2017. Stroke prevention in atrial fibrillation: Past, present and future: Comparing the guidelines and practical decision-making. *Thromb. Haemost.* 117, 1230–1239. <https://doi.org/10.1160/TH16-11-0876>
- Liu, F., Xu, Z., Luo, J., Yu, P., Ma, J., Yuan, P., Zhu, W., 2021. Effectiveness and Safety of DOACs vs. VKAs in AF Patients With Cancer: Evidence From Randomized Clinical Trials and Observational Studies. *Front. Cardiovasc. Med.* 8, 766377. <https://doi.org/10.3389/fcvm.2021.766377>
- Luo, Y., Wang, X., Matsushita, K., Wang, C., Zhao, X., Hu, B., Liu, L., Li, H., Liu, G., Jia, Q., Wang, Yilong, Wang, Yongjun, 2014. Associations Between Estimated Glomerular Filtration Rate and Stroke Outcomes in Diabetic Versus Nondiabetic Patients. *Stroke* 45, 2887–2893. <https://doi.org/10.1161/STROKEAHA.114.005380>
- MacWalter, R.S., Wong, S.Y.S., Wong, K.Y.K., Stewart, G., Fraser, C.G., Fraser, H.W., Ersoy, Y., Ogston, S.A., Chen, R., 2002. Does Renal Dysfunction Predict Mortality After Acute Stroke?: A 7-Year Follow-Up Study. *Stroke* 33, 1630–1635. <https://doi.org/10.1161/01.STR.0000016344.49819.F7>
- Mahdy, M.E., Ghonimi, N.A., Elserafy, T.S., Mahmoud, W., 2019. The NIHSS score can predict the outcome of patients with primary intracerebral hemorrhage. *Egypt. J. Neurol. Psychiatry Neurosurg.* 55, 21. <https://doi.org/10.1186/s41983-019-0056-0>
- Manoukian, S.V., Feit, F., Mehran, R., Voeltz, M.D., Ebrahimi, R., Hamon, M., Dangas, G.D., Lincoff, A.M., White, H.D., Moses, J.W., King, S.B., Ohman, E.M., Stone, G.W., 2007. Impact of Major Bleeding on 30-Day Mortality and Clinical Outcomes in Patients With Acute Coronary Syndromes. *J. Am. Coll. Cardiol.* 49, 1362–1368. <https://doi.org/10.1016/j.jacc.2007.02.027>
- Markidan, J., Cole, J.W., Cronin, C.A., Merino, J.G., Phipps, M.S., Wozniak, M.A., Kittner, S.J., 2018. Smoking and Risk of Ischemic Stroke in Young Men. *Stroke* 49, 1276–1278. <https://doi.org/10.1161/STROKEAHA.117.018859>
- Masotti, L., Campanini, M., 2013. Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics. *Ital. J. Med.* 7, 1. <https://doi.org/10.4081/itjm.2013.s8.1>
- McRae, S., Tran, H., Schulman, S., Ginsberg, J., Kearon, C., 2006. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis 368, 8.

- Meinel, T.R., Branca, M., De Marchis, G.M., Nedeltchev, K., Kahles, T., Bonati, L., Arnold, M., Heldner, M.R., Jung, S., Carrera, E., Dirren, E., Michel, P., Strambo, D., Cereda, C.W., Bianco, G., Kägi, G., Vehoff, J., Katan, M., Bolognese, M., Backhaus, R., Salmen, S., Albert, S., Medlin, F., Berger, C., Schelosky, L., Renaud, S., Niederhauser, J., Bonvin, C., Schaerer, M., Mono, M., Rodic, B., Tarnutzer, A.A., Mordasini, P., Gralla, J., Kaesmacher, J., Engelter, S., Fischer, U., Seiffge, D.J., the Investigators of the Swiss Stroke Registry, 2021. Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation. *Ann. Neurol.* 89, 42–53. <https://doi.org/10.1002/ana.25917>
- Mentias, A., Briasoulis, A., Shantha, G., Alvarez, P., Vaughan-Sarrazin, M., 2019. Impact of Heart Failure Type on Thromboembolic and Bleeding Risk in Patients With Atrial Fibrillation on Oral Anticoagulation. *Am. J. Cardiol.* 123, 1649–1653. <https://doi.org/10.1016/j.amjcard.2019.02.027>
- Mestre, H., Cohen-Minian, Y., Zajarias-Fainsod, D., Ibarr, A., 2013. Pharmacological Treatment of Acute Ischemic Stroke, in: Kishore, U. (Ed.), *Neurodegenerative Diseases*. InTech. <https://doi.org/10.5772/53774>
- Miller, J., Ye, X., Lenhart, G.M., M. Farr, A., Tran, O., Kwong, W.J., Magnuson, E., Weintraub, W., 2016. Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAf) in the US. *Clin. Outcomes Res.* 215. <https://doi.org/10.2147/CEOR.S98888>
- Mittal, S., Goel, D., 2017. Mortality in ischemic stroke score: A predictive score of mortality for acute ishemic stroke. *Brain Circ.* 3, 29–34. <https://doi.org/10.4103/2394-8108.203256>
- Mizokami, Y., Yamamoto, T., Atarashi, H., Yamashita, T., Akao, M., Ikeda, T., Koretsune, Y., Okumura, K., Shimizu, W., Tsutsui, H., Toyoda, K., Hirayama, A., Yasaka, M., Yamaguchi, T., Teramukai, S., Kimura, T., Kaburagi, J., Takita, A., Inoue, H., 2020. Current status of proton pump inhibitor use in Japanese elderly patients with non-valvular atrial fibrillation: A subanalysis of the ANAFIE Registry. *PLOS ONE* 15, e0240859. <https://doi.org/10.1371/journal.pone.0240859>
- Mohan, K.M., Wolfe, C.D.A., Rudd, A.G., Heuschmann, P.U., Kolominsky-Rabas, P.L., Grieve, A.P., 2011. Risk and Cumulative Risk of Stroke Recurrence: A Systematic Review and Meta-Analysis. *Stroke* 42, 1489–1494. <https://doi.org/10.1161/STROKEAHA.110.602615>
- Molteni, M., Cimminiello, C., 2014. Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. *Thromb. J.* 12, 5. <https://doi.org/10.1186/1477-9560-12-5>
- Morady, F., Oral, H., Chugh, A., Pelosi, F., Bogun, F., Good, E., Jongnarangsin, K., Crawford, T., Latchamsetty, R., 2011. The Treatment of Atrial Fibrillation. *Regents Univ. Mich.* 18.

- Moscucci, M., Cannon, C.P., Klein, M., Lopez-Sendon, J., Montalescot, G., White, K., Goldberg, R.J., 2003. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). *Eur. Heart J.* 24, 1815–1823. [https://doi.org/10.1016/S0195-668X\(03\)00485-8](https://doi.org/10.1016/S0195-668X(03)00485-8)
- Namale, G., Kamacooko, O., Makhoba, A., Mugabi, T., Ndagire, M., Ssanyu, P., Ddamulira, J.B.M., Yperzeele, L., Cras, P., Ddumba, E., Seeley, J., Newton, R., 2020. Predictors of 30-day and 90-day mortality among hemorrhagic and ischemic stroke patients in urban Uganda: a prospective hospital-based cohort study. *BMC Cardiovasc. Disord.* 20, 442. <https://doi.org/10.1186/s12872-020-01724-6>
- Nayak, S., Natarajan, B., Pai, R.G., 2020. Etiology, Pathology, and Classification of Atrial Fibrillation. *Int. J. Angiol.* 29, 065–071. <https://doi.org/10.1055/s-0040-1705153>
- Ndrepepa, G., Groha, P., Lahmann, A.L., Lohaus, R., Cassese, S., Schulz-Schüpke, S., Kufner, S., Mayer, K., Bernlochner, I., Byrne, R.A., Fusaro, M., Laugwitz, K.-L., Schunkert, H., Kastrati, A., 2016. Increased bleeding risk during percutaneous coronary interventions by arterial hypertension: Bleeding and Arterial Hypertension. *Catheter. Cardiovasc. Interv.* 88, 184–190. <https://doi.org/10.1002/ccd.26272>
- Ocak, G., Rookmaaker, M.B., Algra, A., de Borst, G.J., Doevendans, P.A., Kappelle, L.J., Verhaar, M.C., Visseren, F.L., the SMART Study Group, 2018. Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study. *J. Thromb. Haemost.* 16, 65–73. <https://doi.org/10.1111/jth.13904>
- Ogata, T., Kamouchi, M., Matsuo, R., Hata, J., Kuroda, J., Ago, T., Sugimori, H., Inoue, T., Kitazono, T., on behalf of the Fukuoka Stroke Registry, 2014. Gastrointestinal Bleeding in Acute Ischemic Stroke: Recent Trends from the Fukuoka Stroke Registry. *Cerebrovasc. Dis. Extra* 4, 156–164. <https://doi.org/10.1159/000365245>
- Ong, C.-T., Sung, S.-F., Wong, Y.-S., Wu, C.-S., Hsu, Y.-C., Su, Y.-H., Li, C.-H., Hung, L.-C., 2016. Risk Factors for In-Hospital Mortality among Ischemic Stroke Patients in Southern Taiwan. *Int. J. Gerontol.* 10, 86–90. <https://doi.org/10.1016/j.ijge.2014.06.013>
- Oral, H., Latchamsetty, R., 2014. Atrial Fibrillation, in: *Cardiac Electrophysiology: From Cell to Bedside*. Elsevier, pp. 739–754. <https://doi.org/10.1016/B978-1-4557-2856-5.00075-3>
- Osório, J., 2012. Aspirin and diabetes mellitus—no increase in bleeding risk? *Nat. Rev. Endocrinol.* 8, 442–442. <https://doi.org/10.1038/nrendo.2012.108>
- Ovbiagele, B., 2011. Chronic kidney disease and risk of death during hospitalization for stroke. *J. Neurol. Sci.* 301, 46–50. <https://doi.org/10.1016/j.jns.2010.11.002>

- Owolabi, M., Akarolo-Anthony, S., Akinyemi, R., Arnett, D., Gebregziabher, M., Jenkins, C., Tiwari, H., Arulogun, O., Akpalu, A., Sarfo, F., Obiako, R., Owolabi, L., Sagoe, K., Melikam, S., Adeoye, A., Lackland, D., Ovbiagele, B., 2015. The burden of stroke in Africa: a glance at the present and a glimpse into the future: review article. *Cardiovasc. J. Afr.* 26, S27–S38. <https://doi.org/10.5830/CVJA-2015-038>
- Oza, R., Rundell, K., 2017. Recurrent Ischemic Stroke: Strategies for Prevention 96, 5.
- Paciaroni, M., Agnelli, G., Micheli, S., Caso, V., 2007. Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke: A Meta-Analysis of Randomized Controlled Trials. *Stroke* 38, 423–430. <https://doi.org/10.1161/01.STR.0000254600.92975.1f>
- Pahuja, M., Chehab, O., Ranka, S., Mishra, T., Ando, T., Yassin, A.S., Thayer, K.L., Shah, P., Kimmelstiel, C.D., Salehi, P., Kapur, N.K., 2021. Incidence and clinical outcomes of stroke in ST -elevation myocardial infarction and cardiogenic shock. *Catheter. Cardiovasc. Interv.* 97, 217–225. <https://doi.org/10.1002/ccd.28919>
- Palareti, G., Cosmi, B., 2009. Bleeding with anticoagulation therapy – Who is at risk, and how best to identify such patients. *Thromb. Haemost.* 102, 268–278. <https://doi.org/10.1160/TH08-11-0730>
- Pamela J, B., Joseph, H., Matthew, K., Thomas G, B., Lee, N., Judith M, K., Jamie M, R., Frank M, S., 2019. Warfarin Use and Mortality, Stroke, and Bleeding Outcomes in a Cohort of Elderly Patients with non-Valvular Atrial Fibrillation. *J. Atr. Fibrillation* 12, 2155. <https://doi.org/10.4022/jafib.2155>
- Pan, Y., Jing, J., Chen, W., Wang, Y., He, Y., 2018. Association between impaired renal function and stroke outcome in patients with versus without atrial fibrillation. *Eur. J. Neurol.* 25, 1041–1048. <https://doi.org/10.1111/ene.13617>
- Patel, J.P., Roberts, L.N., Arya, R., 2011. Anticoagulating obese patients in the modern era: Review. *Br. J. Haematol.* 155, 137–149. <https://doi.org/10.1111/j.1365-2141.2011.08826.x>
- Phan, D., Yang, S.-J., Shen, A.Y.-J., Lee, M.-S., 2019. Effect of Warfarin on Ischemic Stroke, Bleeding, and Mortality in Patients with Atrial Fibrillation Receiving Peritoneal Dialysis. *Am. J. Cardiovasc. Drugs* 19, 509–515. <https://doi.org/10.1007/s40256-019-00347-3>
- Pisters, R., Lane, D.A., Nieuwlaat, R., de Vos, C.B., Crijns, H.J.G.M., Lip, G.Y.H., 2010. A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. *Chest* 138, 1093–1100. <https://doi.org/10.1378/chest.10-0134>
- Pol, T., Held, C., Westerbergh, J., Lindbäck, J., Alexander, J.H., Alings, M., Erol, C., Goto, S., Halvorsen, S., Huber, K., Hanna, M., Lopes, R.D., Ruzyllo,

- W., Granger, C.B., Hijazi, Z., 2018. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. *J. Am. Heart Assoc.* 7, e007444. <https://doi.org/10.1161/JAHA.117.007444>
- Power, A., 2013. Stroke in Dialysis and Chronic Kidney Disease. *Blood Purif.* 36, 179–183. <https://doi.org/10.1159/000356086>
- Powers, W.J., Rabinstein, A.A., Ackerson, T., Adeoye, O.M., Bambakidis, N.C., Becker, K., Biller, J., Brown, M., Demaerschalk, B.M., Hoh, B., Jauch, E.C., Kidwell, C.S., Leslie-Mazwi, T.M., Ovbiagele, B., Scott, P.A., Sheth, K.N., Southerland, A.M., Summers, D.V., Tirschwell, D.L., 2018. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke* 49. <https://doi.org/10.1161/STR.0000000000000158>
- Pullicino, P., Thompson, J.L.P., Barton, B., Levin, B., Graham, S., Freudenberger, R.S., 2006. Warfarin Versus Aspirin in Patients With Reduced Cardiac Ejection Fraction (WARCEF): Rationale, Objectives, and Design. *J. Card. Fail.* 12, 39–46. <https://doi.org/10.1016/j.cardfail.2005.07.007>
- Qian, Y., Ye, D., Wu, D.J., Feng, C., Zeng, Z., Ye, L., Zhu, R., Zhang, Z., Mao, Y., 2019. Role of cigarette smoking in the development of ischemic stroke and its subtypes: a Mendelian randomization study. *Clin. Epidemiol.* Volume 11, 725–731. <https://doi.org/10.2147/CLEP.S215933>
- Rahmadina, A., Gofir, A., Nugroho, A.E., 2015. The Role of Anticoagulation Control on the Mortality Rate in Warfarin Treated Ischemic Stroke Patients with Atrial Fibrillation. 7, 5.
- Ray, W.A., Chung, C.P., Murray, K.T., Smalley, W.E., Daugherty, J.R., Dupont, W.D., Stein, C.M., 2018. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. *JAMA* 320, 2221. <https://doi.org/10.1001/jama.2018.17242>
- Roy-O'Reilly, M., McCullough, L.D., 2018. Age and Sex Are Critical Factors in Ischemic Stroke Pathology. *Endocrinology* 159, 3120–3131. <https://doi.org/10.1210/en.2018-00465>
- Rozjabek, H.M., Coleman, C.I., Ashton, V., Laliberté, F., Oyefesobi, P., Lejeune, D., Germain, G., Schein, J.R., Yuan, Z., Lefebvre, P., Peterson, E.D., 2019. Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants. *J. Med. Econ.* 22, 751–759. <https://doi.org/10.1080/13696998.2019.1603156>
- Ryan, M., Nestor, M., 2020. Stroke, in: *Pharmacotherapy: A Pathophysiologic Approach*. McGraw Hill Medical, New York.

- Savelieva, I., Bajpai, A., John Camm, A., 2007. Stroke in atrial fibrillation: Update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. *Ann. Med.* 39, 371–391. <https://doi.org/10.1080/07853890701320662>
- Saxena, R., Koudstaal, P.J., 2004. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. *Cochrane Database Syst. Rev.* <https://doi.org/10.1002/14651858.CD000187.pub2>
- Saxena, R., Lewis, S., Berge, E., Sandercock, P.A.G., Koudstaal, P.J., for the International Stroke Trial Collaborative Group, 2001. Risk of Early Death and Recurrent Stroke and Effect of Heparin in 3169 Patients With Acute Ischemic Stroke and Atrial Fibrillation in the International Stroke Trial. *Stroke* 32, 2333–2337. <https://doi.org/10.1161/hs1001.097093>
- Sedaghat, M., Lima, B.S., Bouzari, R., Shadlou, S., 2021. Gastrointestinal Bleeding Associated With Warfarin and Rivaroxaban Therapy in Atrial Fibrillation Cases with Concomitant Coagulopathy. *Cardiovasc. Hematol. Disord. Drug Targets.* 21, 123–127. <https://doi.org/10.2174/1871529X20999201231210044>
- Segev, A., Strauss, B.H., Tan, M., Constance, C., Langer, A., Goodman, S.G., 2005. Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: Insights from the Canadian Acute Coronary Syndrome Registries. *Am. Heart J.* 150, 690–694. <https://doi.org/10.1016/j.ahj.2004.11.012>
- Senoo, K., Lane, D., Lip, G.Y., 2014. Stroke and Bleeding Risk in Atrial Fibrillation. *Korean Circ. J.* 44, 281. <https://doi.org/10.4070/kcj.2014.44.5.281>
- Setyopranoto, I., Halwan, F., Andre, S., Sarasiti, A., Lutfan, L., Fatwa, S., Rusdy, G., 2019. Prevalence of Stroke and Associated Risk Factors in Sleman District of Yogyakarta Special Region, Indonesia. *Stroke Res. Treat.* 1–8.
- Shahpour, M.M., Mousavi, S.A., Khorvash, F., Mousavi, S.M., Hoseini, T., 2012. Anticoagulant therapy for ischemic stroke: A review of literature. *J. Res. Med. Sci.* 6.
- Shen, A.Y.-J., Yao, J.F., Brar, S.S., Jorgensen, M.B., Chen, W., 2007. Racial/Ethnic Differences in the Risk of Intracranial Hemorrhage Among Patients With Atrial Fibrillation. *J. Am. Coll. Cardiol.* 50, 309–315. <https://doi.org/10.1016/j.jacc.2007.01.098>
- Siegal, D., Yudin, J., Kaatz, S., Douketis, J.D., Lim, W., Spyropoulos, A.C., 2012. Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists: Systematic Review and Meta-Analysis of Bleeding and Thromboembolic Rates. *Circulation* 126, 1630–1639. <https://doi.org/10.1161/CIRCULATIONAHA.112.105221>

- Silva, R.L., Guhl, E.N., Althouse, A.D., Herbert, B., Sharbaugh, M., Essien, U.R., Hausmann, L.R.M., Magnani, J.W., 2021. Sex differences in atrial fibrillation: patient-reported outcomes and the persistent toll on women. *Am. J. Prev. Cardiol.* 8, 100252. <https://doi.org/10.1016/j.ajpc.2021.100252>
- Smythe, M.A., Parker, D., Garwood, C.L., Cuker, A., Messé, S.R., 2020. Timing of Initiation of Oral Anticoagulation after Acute Ischemic Stroke in Patients with Atrial Fibrillation. *Pharmacother. J. Hum. Pharmacol. Drug Ther.* 40, 55–71. <https://doi.org/10.1002/phar.2345>
- So, C.H., Eckman, M.H., 2017. Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. *J. Thromb. Thrombolysis* 43, 7–17. <https://doi.org/10.1007/s11239-016-1425-5>
- Son, M.K., Lim, N.-K., Kim, H.W., Park, H.-Y., 2017. Risk of ischemic stroke after atrial fibrillation diagnosis: A national sample cohort. *PLOS ONE* 12, e0179687. <https://doi.org/10.1371/journal.pone.0179687>
- Sorensen, S.V., Dewilde, S., Singer, D.E., Goldhaber, S.Z., Monz, B.U., Plumb, J.M., 2009. Cost-effectiveness of warfarin: Trial versus “real-world” stroke prevention in atrial fibrillation. *Am. Heart J.* 157, 1064–1073. <https://doi.org/10.1016/j.ahj.2009.03.022>
- Spence, J.D., 2018. Cardioembolic stroke: everything has changed. *Stroke Vasc. Neurol.* 3, 76–83. <https://doi.org/10.1136/svn-2018-000143>
- Stanton, R.J., Eckman, M.H., Woo, D., Moomaw, C.J., Haverbusch, M., Flaherty, M.L., Kleindorfer, D.O., 2020. Ischemic Stroke and Bleeding. *Am. Heart Assoc.* 51, 7. <https://doi.org/10.1161/STROKEAHA.119.027370>
- Steinberg, B.A., Peterson, E.D., Kim, S., Thomas, L., Gersh, B.J., Fonarow, G.C., Kowey, P.R., Mahaffey, K.W., Sherwood, M.W., Chang, P., Piccini, J.P., Ansell, J., 2015. Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation. *Circulation* 131, 8.
- Tanaka, K., Koga, M., Lee, K.-J., Kim, B.J., Park, E.L., Lee, J., Mizoguchi, T., Yoshimura, S., Cha, J.-K., Lee, B.-C., Nakahara, J., Suzuki, N., Bae, H.-J., Toyoda, K., for the CRCS-K Investigators and the SAMURAI Study Investigators, 2020. Atrial Fibrillation-Associated Ischemic Stroke Patients With Prior Anticoagulation Have Higher Risk for Recurrent Stroke. *Stroke* 51, 1150–1157. <https://doi.org/10.1161/STROKEAHA.119.027275>
- Toyoda, K., Yasaka, M., Iwade, K., Nagata, K., Koretsune, Y., Sakamoto, T., Uchiyama, S., Gotoh, J., Nagao, T., Yamamoto, M., Takahashi, J.C., Minematsu, K., 2008. Dual Antithrombotic Therapy Increases Severe Bleeding Events in Patients With Stroke and Cardiovascular Disease: A Prospective, Multicenter, Observational Study. *Stroke* 39, 1740–1745. <https://doi.org/10.1161/STROKEAHA.107.504993>

- Tseng, E., Crowther, M.A., Hillis, C.M., 2016. Bridging anticoagulation for interruption of warfarin in a patient with atrial fibrillation. *Can. Med. Assoc. J.* 188, 361–362. <https://doi.org/10.1503/cmaj.150867>
- van Rein, N., Heide-Jørgensen, U., Lijfering, W.M., Dekkers, O.M., Sørensen, H.T., Cannegieter, S.C., 2019. Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy: Results From a Nationwide Danish Cohort Study. *Circulation* 139, 775–786. <https://doi.org/10.1161/CIRCULATIONAHA.118.036248>
- Vemmos, K.N., Tsivgoulis, G., Spengos, K., Zakopoulos, N., Synetos, A., Manios, E., Konstantopoulou, P., Mavrikakis, M., 2004. U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. *J. Intern. Med.* 255, 257–265. <https://doi.org/10.1046/j.1365-2796.2003.01291.x>
- Verdecchia, P., Angeli, F., Reboldi, G., 2018. Hypertension and Atrial Fibrillation. *Am. Heart Assoc.* 122, 17. <https://doi.org/10.1161/CIRCRESAHA.117.311402>
- Vinding, N.E., Kristensen, S.L., Rørth, R., Butt, J.H., Østergaard, L., Olesen, J.B., Torp-Pedersen, C., Gislason, G.H., Køber, L., Kruuse, C., Johnsen, S.P., Fosbøl, E.L., 2022. Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation. *J. Am. Heart Assoc.* 11, e022638. <https://doi.org/10.1161/JAHA.121.022638>
- Wachtel, T.J., 2007. Geriatric clinical advisor: instant diagnosis and treatment. Elsevier Mosby, Philadelphia.
- Walkey, A.J., Wiener, R.S., Ghobrial, J.M., Curtis, L.H., Benjamin, E.J., 2011. Incident Stroke and Mortality Associated With New-Onset Atrial Fibrillation in Patients Hospitalized With Severe Sepsis. *JAMA* 306. <https://doi.org/10.1001/jama.2011.1615>
- Wang, C., Wu, V.C., Huang, Y., Kuo, C., Chu, P., Chen, Y., Wen, M., Chang, S., 2019. Safety and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study. *J. Am. Heart Assoc.* 8. <https://doi.org/10.1161/JAHA.119.012029>
- Wang, Yilong, Xu, J., Zhao, X., Wang, D., Wang, C., Liu, L., Wang, A., Meng, X., Li, H., Wang, Yongjun, 2013. Association of Hypertension With Stroke Recurrence Depends on Ischemic Stroke Subtype. *Stroke* 44, 1232–1237. <https://doi.org/10.1161/STROKEAHA.111.000302>
- Waranugraha, Y., Rizal, A., Syaban, M.F.R., Faratisha, I.F.D., Erwan, N.E., Yunita, K.C., 2021. Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: a systematic review and meta-analysis of real-world evidences. *Egypt. Heart J.* 73, 70. <https://doi.org/10.1186/s43044-021-00194-1>

- Warden, B.A., Diep, C., Ran, R., Thomas, M., Cigarroa, J.E., 2019. The effect of heparin infusion intensity on outcomes for bridging hospitalized patients with atrial fibrillation. *Clin. Cardiol.* 42, 995–1002. <https://doi.org/10.1002/clc.23256>
- Wetmore, J.B., Herzog, C.A., Sexter, A., Gilbertson, D.T., Liu, J., Kasner, S.E., 2020. Outcomes Following Ischemic Stroke in Older Patients With CKD Stages 4 and 5: A Retrospective Cohort Study. *Am. J. Kidney Dis.* 76, 784–793. <https://doi.org/10.1053/j.ajkd.2020.03.021>
- WHO, 2016. Tobacco & Stroke. World Health Organ.
- WHO, [World Health Organization], 2018. The Top 10 Causes of Death.
- WHO, [World Health Organization], 2012. Indonesia: WHO Statistical Profile.
- Woo, H.G., Chung, I., Gwak, D.S., Kim, B.K., Kim, B.J., Bae, H.-J., Han, M.-K., 2019. Recurrent ischemic stroke in atrial fibrillation with non-vitamin K antagonist oral anticoagulation. *J. Clin. Neurosci.* 64, 127–133. <https://doi.org/10.1016/j.jocn.2019.03.037>
- Wu, E., Howard, G., Milena, M., Edward, T., Adam, R., Warren, J., Jeremy, R., 2015. Economic Burden and Co-Morbidities of Atrial Fibrillation in a Privately Insured Population. *Curr. Med. Res. Opin.* 21(10), 1693–1699.
- Wysowski, D.K., Nourjah, P., Swartz, L., 2007. Bleeding Complications With Warfarin Use: A Prevalent Adverse Effect Resulting in Regulatory Action. *Arch. Intern. Med.* 167, 1414. <https://doi.org/10.1001/archinte.167.13.1414>
- Xian, Y., Wu, J., O'Brien, E.C., Fonarow, G.C., Olson, D.M., Schwamm, L.H., Bhatt, D.L., Smith, E.E., Suter, R.E., Hannah, D., Lindholm, B., Maisch, L., Greiner, M.A., Lytle, B.L., Pencina, M.J., Peterson, E.D., Hernandez, A.F., 2015. Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. *BMJ* h3786. <https://doi.org/10.1136/bmj.h3786>
- Yamashita, Y., Morimoto, T., Toyota, T., Shiomi, H., Makiyama, T., Ono, K., Kimura, T., 2018. Asian patients versus non-Asian patients in the efficacy and safety of direct oral anticoagulants relative to vitamin K antagonist for venous thromboembolism: A systemic review and meta-analysis. *Thromb. Res.* 166, 37–42. <https://doi.org/10.1016/j.thromres.2018.04.008>
- Yong, J.W., Yang, L.X., Ohene, B.E., Zhou, Y.J., Wang, Z.J., 2017. Periprocedural heparin bridging in patients receiving oral anticoagulation: a systematic review and meta-analysis. *BMC Cardiovasc. Disord.* 17, 295. <https://doi.org/10.1186/s12872-017-0719-7>
- Yuan, M., Li, Q., Zhang, R., Zhang, W., Zou, N., Qin, X., Cai, Z., 2021. Risk factors for and impact of poststroke pneumonia in patients with acute ischemic

stroke. *Medicine* (Baltimore) 100, e25213.
<https://doi.org/10.1097/MD.00000000000025213>

Zhou, Y., Ma, J., Zhu, W., 2020. Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation Across BMI Categories: A Systematic Review and Meta-Analysis. *Am. J. Cardiovasc. Drugs* 20, 51–60. <https://doi.org/10.1007/s40256-019-00362-4>

Zhu, W., Guo, L., Liu, F., Wan, R., Shen, Y., Lip, G.Y.H., Hong, K., 2017. Efficacy and safety of triple *versus* dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis. *Oncotarget* 8, 81154–81166. <https://doi.org/10.18632/oncotarget.20870>

Zipes, D.P., Jalife, J., Stevenson, W.G. (Eds.), 2018. *Cardiac electrophysiology: from cell to bedside*, Seventh edition. ed. Elsevier, Philadelphia, PA.